1.. Background {#s6}
==============

Depression is a common mental disorder and a leading cause of disease burden in the elderly population. According to data from the World Health Organization, the prevalence of depression in elderly individuals is between 3 and 10%.[@B1] Geriatric depression usually refers to depression among individuals 60 years of age or older.[@B2] Slow onset and atypical symptoms (e.g., relatively mild depressive symptoms and frequent concurrent somatic symptoms) are common in geriatric depression, which makes it easy to overlook. Failure to identify and treat geriatric depression can exacerbate the decline in physical functioning due to concurrent physical illnesses, increase the level of disability, and, thus, substantially decrease the individual's quality of life.[@B3]

Using a selective serotonin re-uptake inhibitor (SSRI) is the recommended first-line treatment for geriatric depression in most high-income countries. But these medications have many side-effects -- some of which are serious[@B4] -- that increase in prevalence and severity with increased dosage and that may be more prevalent and less tolerated in elderly individuals. The initial dose of antidepressant medication used for geriatric depression is usually relatively low due to clinicians' concerns about serious side effects or interactions with other medications being used for physical illnesses. Partly due to this reason (i.e., using sub-optimal dosages), the treatment effect of common antidepressants in geriatric depression is not as robust as that in younger adults; moreover, geriatric patients who consider the medications less effective are often non-compliant with anti-depressant treatment. Many of these untreated or inadequately treated individuals become chronically depressed.

Chinese herbal medicines have been widely used in the treatment of depression. Shuganjieyu, which is composed of St. John's wort and extracts of Siberian ginseng, is the first Chinese herb-based medication approved by the Chinese drug regulatory agency (CFDA) for the treatment of depression (approved in 2008). It has been shown to be effective, safe, and well tolerated.\[[@B5]-[@B7]\] The main ingredients of shuganjieyu are hypericum perforatum and acanthopanax extract. The antidepressant effect of hypericum perforatum, which has a mechanism of action similar to that of SSRIs, has been well recognized.[@B8] Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive intervention that has also been shown to be a safe and effective treatment for depression in China and abroad.\[[@B9]-[@B11]\] This study aims to evaluate the efficacy and safety of shuganjieyu for geriatric depression when used with or without adjunctive treatment with rTMS.

2.. Methods {#s7}
===========

2.1. Sample {#s7a}
-----------

Figure 1 shows the enrollment of subjects in the study. Study participants were 65 patients with geriatric depression admitted to the Third Hospital of Daqing Municipality between December 2013 and September 2014. The inclusion criteria were as follows. (a) Met the diagnostic criteria for depression according to the 10^th^ edition of the International Classification of Diseases (ICD-10)[@B12] and had not been taking antidepressants in the two weeks prior to enrollment. (b) Met the classification of 'liver stagnation and spleen deficiency' based on Traditional Chinese Medicine theories.[@B13] \[Symptoms of stagnated liver energy ('qi') include uncoordinated mood and will, lack of aspiration, and low mood; symptoms of spleen deficiency include emotional distress, restlessness, poor memory, insomnia, dizziness and poor appetite.\] (c) Aged 60 years or older. (d) Scored no less than 18 points on the 17-item version of the Hamilton Rating Scale for Depression (HAMD-17).[@B14] (e) Were willing to participate and signed the informed consent form (or their guardian signed the consent form). (f) Were in good physical health based on the baseline physical examination, electrocardiogram (EKG), clinical laboratory test results, and medical history. Exclusion criteria included (a) having suicidal tendencies; (b) the presence of serious heart, liver, or kidney dysfunction or any disease of the endocrine system; (c) had a history of epilepsy; (d) had a history of psychoactive substance dependence (including alcohol); (e) had depression induced by other mental or physical conditions; (f) had a bipolar disorder; (g) were unfit for rTMS treatment; (h) were allergic to hypericum perforatum or acanthopanax; (i) had abnormal EKG or laboratory test results; (j) had a history of poor medication compliance; or (k) had received electroconvulsive therapy in the month prior to enrollment.

![Flowchart of the study](sap-27-02-103-g002){#sap-27-02-103-g002.tif}

2.2. Intervention {#s7b}
-----------------

Patients who met the inclusion criteria were randomly assigned to the experiment or control group using a random number table. Shuganjieyu provided by Chengdu Kanghong Pharmaceuticals Co. Ltd., (China SFDA No. Z20080580) were used in the study. Patients in both groups received two capsules of shuganjieyu immediately after meals, twice a day for six weeks. Participants in the experiment group were also treated with rTMS (using equipment from the Magstim Co., Ltd, UK) with the coil located above the left dorsolateral prefrontal cortex; participants in the control group were given mock-rTMS in which the coil touched the scalp but no stimulation was provided. The rTMS stimulation was of low intensity (30% MT) and low frequency (10HZ). Each session lasted for an average of 20 minutes. A total of 20 rTMS sessions were administered in four 5-day cycles with 2-day breaks between cycles. All participants and evaluators were masked during the trial. For patients who experienced sleep problems during the treatment, zopiclone or benzodiazepines were allowed for short-term treatment.

2.3. Assessment of efficacy {#s7c}
---------------------------

The Hamilton Rating Scale for Depression-17 Item (HAMD-17) was used to assess efficacy and the Treatment Emergent Symptom Scale (TESS) was used to assess safety.[@B14] The two scales were administered at 1 week, 2 weeks, 4 weeks, and 6 weeks after the initiation of the treatment. The reported inter-rater reliability of the Chinese version of HAMD-17, based on the correlation of total scores between independent raters, is between 0.88 and 0.99 and its validity, based on the correlation or the total score and clinical ratings of the severity of depression, is 0.92.[@B15] Two trained associate senior clinicians conducted these evaluations in this study; the inter-relater reliability of their HAMD-17 total was good (Kappa 0.75 to 0.86). Routine blood tests, tests of liver and kidney function, and EKGs were also assessed at the same time periods.

The main measure of efficacy was the percent reduction from baseline HAMD-17 scores (\[pretreatment score - post-treatment score\]/pretreatment score x 100%) at the end of the trial. Efficacy was categorized into remitted (reduction \>75% or total HAMD-17 score \<7), significantly improved (reduction=50 to 74%), improved (reduction=25 to 49%), and not improved (reduction \<25%).

The HAMD-17 can be divided into 5 subscales:\[[@B16],[@B17]\] (a) 4 items in the retardation subscale assess depressed mood, work and activities, psychomotor retardation, and loss of sexual interest; (b) 3 items assess guilt, suicidal ideation, and psychomotor agitation; (c) 3 items assess sleep problems including difficulty of falling asleep, light sleep, and early awakening; (d) 6 items assess anxiety and somatic symptoms including mental anxiety, somatic anxiety, gastrointestinal symptoms, hypochondriasis, insight, and general somatic symptoms. And (e) 1 item assesses loss of weight.

2.4. Statistical analysis {#s7d}
-------------------------

SPSS 19.0 was used for data analysis. Means and standard deviations were provided. ANCOVA and repeated measures ANOVA (for HAMD-17 scores) were used to compare differences over time and cross groups. Two-sample t-test was used to compare cross-group differences and one-sample t-test was used to assess within-group differences (i.e., compared to baseline). Chi-squared test was used to compare categorical variables and Mann-Whitney rank test was use to compare continuous variables that were not normally distributed.

3.. Results {#s8}
===========

3.1. Characteristics of participants {#s8a}
------------------------------------

Figure 1 shows the flowchart for the study. A total of 65 patients met the inclusion criteria, among whom 36 were assigned to the experiment group and 29 to the control group. In the experiment group, 1 patient dropped out from the study due to early hospital discharge; in the control group the diagnosis was changed to schizophrenia 1 week after admission in 1 patient and another 2 patients dropped out of the study because of early hospital discharge. Therefore, the final analysis included 35 individuals in the experiment group and 26 in the control group. The study completion rate was 97.2% (35/36) in the experimental group and 89.7% (26/29) in the control group. Table 1 shows the characteristics of the individuals who completed the 6-week study; there are no significant differences in gender, age, duration or illness or baseline total HAMD-17 total score between the two groups.

###### 

Characteristics of study participants

  -----------------------------------------------------------------------------------------
  characteristic               experimental group\   control group\   statistic (p-value)
                               (n=35)                (n=26)           
  ---------------------------- --------------------- ---------------- ---------------------
  Gender                                                              

  male, n (%)                  12 (34.3%)            8 (30.8%)        *χ*^2^=0.08 (0.772)

  female, n (%)                23 (63.7%)            18 (69.2%)        

  Age in years                                                        

  range                        60-78                 60-76            *F*=1.42 (0.237)

  mean (sd)                    65.3 (5.1)            64.7 (4.2)        

  Months duration of illness                                          

  range                        1-360                 1-240            *Z*=0.044 (0.965)

  median (IQR)                 60 (24,156)           90 (21, 120)      

  Baseline HAMD-17 score                                              

  range                        18-29                 18-25            *F*=0.20 (0.653)

  mean (sd)                    21.11 (2.93)          20.62 (2.610)     
  -----------------------------------------------------------------------------------------

HAMD-17, 17-item version of the Hamilton Rating Scale for Depression

IQR, interquartile range

3.2. Comparison of efficacy {#s8b}
---------------------------

As shown in Table 2, based on the results of the repeated measures ANOVA, there were no significant cross-group differences (*F*=0.46, *p*=0.502) or differences in group-time interaction (*F*=1.07, *p*=0.352) in HAMD-17 total scores. However, HAMD-17 scores changed significantly over time (*F*=395.91, *p*\<0.001). There was a gradual decrease in the measured severity of depressive symptoms over the six weeks of treatment that was similar in the two groups; by the end of the 6 weeks the mean HAMD-17 score in both groups had dropped by more than 37%.

###### 

Comparison of mean (sd) Hamilton Depression Rating Scale (HAMD-17) scores and the percent change in the scores from baseline during the 6 weeks of treatment in the experimental and control groups^a^

  -------------------------------------------------------------------------------------------------------------------
  **group**               **baseline**\   **1 week**\        **2 weeks**\       **4 weeks**\       **6 weeks**\
                          mean (sd)       mean (sd)\         mean (sd)\         mean (sd)\         mean (sd)\
                                          \[% change\]       \[% change\]       \[% change\]       \[% change\]
  ----------------------- --------------- ------------------ ------------------ ------------------ ------------------
  experimental group\     21.11 (2.93)    19.60 (2.93)^b^\   17.43 (2.87)^b^\   14.57 (3.24)^b^\   13.06 (3.30)^b^\
  (n=35)                                  \[-7.2%\]          \[-17.4%\]         \[-31.0%\]         \[-38.1%\]

  control group\          20.62 (2.61)    18.77 (2.67)\      16.65 (2.71)^b^\   14.35 (3.07)^b^\   13.00 (2.91)^b^\
  (n=26)                                  \[-9.0%\]          \[-19.3%\]         \[-30.4%\]         \[-37.0%\]

  comparison of groups\   0.47 (0.494)    1.29 (0.261)       1.14 (0.291)       0.08 (0.785)       0.01 (0.944)
  F-value (p-value)                                                                                
  -------------------------------------------------------------------------------------------------------------------

^a^ repeated measures ANOVA found a significant difference over time (*F*~time~=395.94, *p*\<0.001), no significant difference by treatment group (*F*~group~=0.46, *p*=0.502), and no significant interaction between treatment group and time (*F*~group\ x\ time~=1.07, *p*=0.352)

^b^ comparison with baseline using two-sample t-test is statistically significant (*p*\<0.001)

At the end of the trial (after 6 weeks of treatment), the two groups had similar efficacy. Using the classification system described in the methods section based on the percent change in the baseline HAMD 17 score, among the 35 patients in the experimental group who completed the 6 weeks of treatment, 1 had fully remitted, 6 were significantly improved, 27 were improved, and 1 was unchanged; thus the overall efficacy was 97.1% (34/35). Among the 26 patients in the control group who completed the treatment, 1 had fully remitted, 4 were significantly improved, 20 were improved, and 1 was unchanged; thus the overall efficacy was 96.2% (25/26). However, among the 61 patients from both groups who completed 6 weeks of treatment, only 2 (3.3%) remitted and only a further 10 (16.4%) had significant improvement; the remaining 80.3% (49/61) had less than 50% reduction in their baseline HAMD-17 scores. That is, by the end of the trial only 20% (7/35) of experimental groups subjects and 19% (5/26) of control groups subjects had experienced significant improvement (or remission) of their depressive symptoms.

Table 3 presents comparisons of the five HAMD-17 subscale scores. All of the subscales showed a dramatic drop in the mean scores over the 6 weeks of the trial, but there were no significant differences between the experimental and control groups in the magnitude or pace of the improvement. There were some minor differences in the rate of improvement for the five subscales: after 1 week of treatment, the improvement in sleep and anxiety/somatic symptoms had already become statistically significant, the improvement in weight loss was only significant in the control group, the improvement in the 'guilt, suicidal ideation, and agitation' subscale was only significant in the experimental group, and neither of the groups showed statistically significant improvement in psychomotor retardation. However, by the end of the second week of treatment both groups showed statistically significant improvement over baseline in all five HAMD-17 subscales scores.

###### 

Comparison of mean (sd) factors scores of Hamilton Depression Rating Scale (HAMD-17) before and after treatment in the experimental and control groups^a^

  ----------------------------------------------------------------------------------------------------------------------------------------------------------
  factor                       group          baseline         1 week           2 weeks          4 weeks          6 weeks          *F*~time~   *p*
  ---------------------------- -------------- ---------------- ---------------- ---------------- ---------------- ---------------- ----------- -------------
  retardation                  experimental   6.74 (1.17)      6.66 (1.21)      6.29 (1.23)^c^   5.34 (1.21)^c^   4.89 (1.13)^c^   97.18       **\<0.001**

  control                      6.62 (1.84)    6.50 (1.79)      5.81 (1.42)^c^   5.27 (1.54)^c^   4.65 (1.38)^c^                                

  guilt, suicidal ideation,\   experimental   2.31 (1.53)      2.06 (1.33)^b^   1.83 (1.22)^b^   1.49 (1.27)^c^   1.23 (1.03)^c^   39.76       **\<0.001**
  and agitation                                                                                                                                

  control                      2.42 (1.27)    2.19 (1.13)      1.96 (1.11)^b^   1.54 (0.95)^c^   1.35 (1.02)^c^                                

  sleep problems               experimental   4.40 (1.22)      3.63 (1.35)^c^   3.09 (1.10)^c^   2.34 (1.16)^c^   2.23 (1.17)^c^   129.33      **\<0.001**

  control                      4.31 (0.97)    3.58 (0.99)^c^   3.19 (1.20)^c^   2.54 (1.21)^c^   2.27 (1.22)^c^                                

  anxiety/somatic\             experimental   6.77 (1.97)      6.46 (1.84)^b^   5.63 (1.90)^c^   4.80 (1.88)^c^   4.14 (1.68)^c^   74.88       **\<0.001**
  symptoms                                                                                                                                     

  control                      6.31 (1.54)    5.88 (1.53)^b^   5.19 (1.55)^c^   4.58 (1.53)^c^   4.31 (1.64)^c^                                

  weight loss                  experimental   0.86 (0.85)      0.77 (0.81)      0.60 (0.70)^b^   0.51 (0.61)^c^   0.43 (0.56)^c^   18.54       **\<0.001**

  control                      0.81 (0.80)    0.58 (0.70)^b^   0.58 (0.70)^b^   0.31 (0.55)^c^   0.31 (0.47)^c^                                
  ----------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ There was no statistically significant difference between the two groups on any of the factors at any of the time points

^b^ *p*\<0.05 for one-sample t-test comparison with baseline score;

^c^ *p*\<0.001 for one-sample t-test comparison with baseline score

3.3. Comparison of safety {#s8c}
-------------------------

No severe adverse events occurred during the trial. Most adverse events occurred early in the study. There were a total of 15 events in 14 individuals (40%) in the experiment group: 2 had dry mouth (5.7%), 3 had headaches or discomfort in the head (8.6%), 2 experienced dizziness (5.7%), 3 had constipation (8.6%), 3 had nausea (8.6%), 1 had excessive sweating (2.9%), and 1 had poor appetite (2.9%). There were a total of 13 events in 13 individuals (50%) in the control group: 3 had dry mouth (11.5%), 2 had headaches (7.7%), 4 experienced dizziness (15.4%), 1 had a stuffy nose (3.85%), 1 had constipation (3.9%), 1 had diarrhea (3.9%), and 1 had poor appetite (3.9%). All of these adverse events remitted spontaneously without any treatment; none of them were severe enough to require discontinuation of the treatment. The proportions of patients in the experimental and control groups who experienced adverse events were not statistically significant (40% v. 50%; *χ^2^*=0.605, *p*=0.437).

4.. Discussion {#s9}
==============

4.1. Main findings {#s9a}
------------------

In this double-blind randomized controlled trial that used changes in HAMD-17 total scores as the main outcome measure, we found comparable effectiveness of the Chinese herbal medicine shuganjieyu with or without adjunctive rTMS in the inpatient treatment of geriatric depression. Ninety-four percent (61/65) of the enrolled subjects completed the 6-week trial. None of the patients experienced serious side effects. Minor side effects occurred in 40% of patients treated with shuganjie and rTMS (the experimental group) and in 50% of patients treated with shuganjie and sham rTMS (the control group); all of these side effects resolved spontaneously and none of them required withdrawal from the study. We conclude that combined treatment with shuganjieyu and rTMS is safe.

Improvement in depressive symptoms was progressive over the 6-week trial; by the end of the 6 weeks the mean overall HAMD-17 score had dropped by 38% in the experimental group and 37% in the control group. The failure to identify a significant time by group interaction in the repeated measures ANOVA suggests that rTMS does not result in a more rapid onset of treatment, as has been suggested by other authors.[@B11] Using a drop in HAMD-17 score from baseline of 25% or greater as the cutoff for 'efficacy', by the end of the trial efficacy was 97% in the experimental group and 96% in the control group. However, using a drop in the HAMD-17 score from baseline of 50% or greater as the cutoff for 'significant improvement', only 20% (7/35) of the patients in the experimental group and 19% (5/26) of the patients in the control group had a significant improvement in their depressive symptoms by the end of the 6 weeks of treatment.

When considering the five subscales of HAMD-17, there were some minor, non-significant differences in the onset of the treatment effect between the different subscales, but all five subscales showed statistically significant improvement after two weeks of treatment in both treatment groups.

4.2. Limitations {#s9b}
----------------

The 97% 'efficacy' of shuganjieyu appears promising but the picture looks quite different when one realizes that only 20% of patients had a 50% or greater improvement in their depressive symptoms over the 6-week trial. In the absence of a full placebo control group or an SSRI comparison group one cannot be certain that the observed improvement in both groups was the result of shuganjieyu treatment \-- it could have been related to the placebo effect of being hospitalized. Studies using different types of comparison groups will be needed to resolve this issue.

This study was conducted in an inpatient setting with patients who had relatively severe depressive symptoms. It is unknown whether or not the outcome would be the same in less-severe, community-based patients. In particular, the use of rTMS, which required daily sessions at a medical setting over several weeks, may not be feasible for most community-based patients.

The failure to find any significant differences between the two groups may be because we did not use the optimal configuration, frequency, and duration of rTMS. The optimal parameters may be different in elderly individuals, so considerable work will be needed to establish standardized methods for administering rTMS in geriatric depression. Larger studies conducted for longer periods may identify significant differences when rTMS is used as an adjunctive treatment for shuganjieyu, but this would probably only be practical in inpatient settings. There may be specific subgroups of patients for whom rTMS is a useful adjunctive treatment, but larger studies would be needed to compare differences between different subgroups of patients to help identify the subgroups in which rTMS is useful.

4.3. Implications {#s9c}
-----------------

We confirm the efficacy and safety of the Chinese herbal medicine shuganjieyu in the treatment of geriatric depression. However, after 6 weeks of treatment only 20% of the subjects had a significant improvement in their depressive symptoms (defined as a 50% drop in the baseline HAMD-17 score) so the value of this medicine as a first-line treatment for geriatric depression may be limited. Shuganjieyu may, however, be useful as a second-line treatment for elderly individuals who cannot tolerate SSRIs. We did not find that adjunctive treatment with rTMS improved overall outcomes for shuganjieuyu or resulted in a more rapid onset of action, though larger samples and longer follow-up studies may be needed to definitively address this issue.
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